Understanding response to rituximab treatment in rheumatoid arthritis through immune fingerprinting of T and B cells

Despite the great research advances in dissecting the mechanisms underlying rheumatoid arthritis onset and development, the exact pathophysiology of this disease remains unsolved. In the past years, the introduction of biologicals, and in particular of therapeutic monoclonal antibodies (mAb), has constituted a major breakthrough in the clinical management of the disease. Although these